专利号:US-2024197774-A1 优先权日:2021-04-16 标 题:Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles 发明人:LOPEZ-RIBOT JOSE; VAZQUEZ-MUNOZ ROBERTO 权利人:UNIV TEXAS 摘要:Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.
专利号:US-8557979-B2 优先权日:2004-06-10 标题 :Carbapenem antibacterials with gram-negative activity and processes for their preparation 发明人:CHOI WOO-BAEG; KOWALIK EWA 权利人:CHOI WOO-BAEG; KOWALIK EWA; FOB SYNTHESIS INC 摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of β-methyl carbapenems which are useful as antibacterial agents.
专利号:US-10933051-B2 优先权日:2017-06-09 标 题 :Carbapenem compounds and compositions for the treatment of bacterial infections 发明人:CHOI WOO-BAEG; TOMIOKA TAKASHI; JOO HYUNG-YEUL; TRUONG PHONG; MIN BRIAN 权利人:FOB SYNTHESIS INC 摘要:The present invention provides carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections, including drug resistant or multiple-drug resistant bacterial infections, and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
专利号:US-9693999-B2 优先权日:2011-01-26 标题:Small molecule RNase inhibitors and methods of use 发明人:DUNMAN PAUL M; OLSON PATRICK D; CHILDERS WAYNE 权利人:UNIV ROCHESTER; UNIV NEBRASKA; Temple University—Of the Commonwealth System of Higher Education 摘要:Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.
专利号:US-9937151-B2 优先权日:2010-06-18 标题 :Carbapenem antibacterials with gram-negative activity 发明人:CHOI WOO-BAEG; GRUSZECKA-KOWALIK EWA; JOO HYUNG-YEUL; LIU SHUANGPEI; MAO SHULI; LI YONGFENG; KIM DEOG-IL 权利人:FOB SYNTHESIS INC 摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
专利号:WO-9302193-A1 优先权日:1991-07-19 标题:cDNAS DERIVED FROM HEPATITIS C VIRUS 发明人:BARTOLOME NEBREDA FERNANDO JAV; CARRENO GARCIA VICENTE; CASTILLO AGUILAR INMACULADA; QUIROGA ESTEVEZ JUAN ANTONIO 权利人:BARTOLOME NEBREDA FERNANDO JAV; CARRENO GARCIA VICENTE; CASTILLO AGUILAR INMACULADA; QUIROGA ESTEVEZ JUAN ANTONIO 摘要:There is provided a series of sequences of cDNAS derived from hepatitis C virus (HCV). The comparison of the sequences of cDNAS obtained shows that they do not have any substantial homology with viruses A, B, and D of hepatitis. The comparison of these cDNAS with the disclosed sequences of HCV isolated in the United States and Japan shows a difference in this region of about 20 % with the one corresponding to that of the virus isolated in the United States and of about 10 % with the virus isolated in Japan. The sequences of cDNAS of HCV are useful for constructing probes and for the synthesis of polypeptides which may be used in immunoassays for diagnosis, control and follow-up in therapy, and developments of vaccines against hepatitis by C virus. The polypeptides coded by the sequences of cDNAS may also be used to produce and purify antibodies to antigens of HCV, as well as immunoassays to detect antigens of C virus. These antibodies may be used in the profilaxis of the infection. Background: hepatitis C is a disease which progresses, in half of the cases, by chronicity and is agressive since in 20 % of chronic cases a hepatic cirrhosis develops. One of the viruses responsible for this disease has been isolated in the United States from serum and liver of chimpanzee which had been previously inoculated with serum originating from a patient affected by hepatitis non-A, non-B (1). Subsequently, a related virus (2, 3) was isolated in Japan.